Case reports: efalizumab-associated lymphoproliferative disease.

Satya Bommakanti, Amol Patil, Camellia Eshoa, Christopher R. Chitambar

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Efalizumab is an immunosuppressive agent that has been approved for the treatment of psoriasis. There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development. To our knowledge, this is the first documented case of a patient who developed Epstein Barr Virus-associated large B cell lymphoma after treatment with efalizumab for psoriasis. As immunosuppressive medications such as efalizumab get increasingly prescribed, the likelihood of seeing various malignancies will increase. Thus, physicians need to have a high index of suspicion for malignancy in patients on immunosuppressive medications like efalizumab.

Original languageEnglish (US)
Pages (from-to)646-648
Number of pages3
JournalJournal of drugs in dermatology : JDD
Volume6
Issue number6
StatePublished - Jun 2007

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Case reports: efalizumab-associated lymphoproliferative disease.'. Together they form a unique fingerprint.

Cite this